ASPirin in Immune thRombocytopenia Patients With Cardiovascular disEase
The incidence of immune thrombocytopenia increases with older age. This population is at risk for arterial thrombosis. Due to an increased turn-over of platelets, low-dose aspirin once daily may be insufficient in this population to protect against arterial thrombosis. This study is aimed at assessing the pharmacodynamics of aspirin once daily on platelet function in these patients.
• adult patients
• non-treated immune thrombocytopenia or immune thrombocytopenia with stable treatment (at least 1 month)
• treated with aspirin daily for a cardiovascular disease; stable platelet count \< 100 x 109/L
• at least one month following an arterial thrombosis
• no other antiplatelet drug and anticoagulant
• female patient with childbearing potential must have acceptable method of birth control
• affiliated or benefiting from public health insurance